Clinical Research

Asking Volunteers to Guess What They Took in a Cannabinoid Trial

·

A clinical trial participant considering a treatment questionnaire.

Imagine a volunteer at the end of a pain experiment. Her pain has eased, and when asked which treatment she thinks she received, she picks the active one. Did recognizing the drug make relief more likely, or did relief persuade her that she had recognized the drug? Even if she guessed correctly, the answer on the form cannot settle the order of events. Moving the question an hour earlier might tell quite a different story.

The moment a treatment gives itself away

In a blinded trial, researchers try to keep the treatment assignment unknown to participants and, often, to the people assessing them. Identical bottles and a concealed randomization list can keep the answer secret right up to administration. After that, a drug with noticeable effects sets a harder test. A participant familiar with THC may recognize a change in how her body feels long before anyone asks about her pain.

A review of blinding in cannabinoid analgesia research examines this difficulty. Recognizing a sensation and identifying a treatment are separate achievements. Someone can feel lightheaded, attribute it to the active drug and turn out to have received placebo. Another volunteer might correctly identify the active treatment from a familiar sensation that has little to do with pain relief. A tally of right answers collapses those experiences into a single column.

Two guesses in one experiment

A controlled experiment in people with fibromyalgia provides an unusually clear view of the clock. Participants received different cannabis preparations and placebo on separate visits. Investigators assessed blinding shortly after inhalation and again at the end of the experiment. Immediately after the active preparations, around half of the participants could not identify what they had received. By the end, people were much better at recognizing two of the active preparations.

Those early and late answers belong on the same page. The earlier one catches clues available soon after inhalation. The later one includes everything the participant has learned in the meantime, including how the drug felt as its effects developed and how she responded during testing. The change tells us that an assignment can become easier to recognize over a session. It does not tell us which of those clues did the work.

Keep the uncertain answers

A participant who says “I don’t know” has supplied information. Forcing her to choose turns uncertainty into a coin toss, half of which may look like successful recognition. The fibromyalgia team used a blinding index developed by Heejung Bang and colleagues and examined the treatment conditions separately. That separation matters. If everyone says “active,” some guesses will inevitably be correct, even though nobody has distinguished one preparation from another.

What a guess adds to a pain score

There is a tempting shortcut here. If a participant guesses correctly and reports less pain, one might discard the improvement as expectation. Yet pain relief itself is among the reasons someone might guess correctly. Removing people on the basis of their answer could remove precisely the people who responded to treatment, disturbing the comparison random assignment was meant to create.

The mirror-image mistake is to call every improvement on placebo an effect of expectation. In a review of placebo-controlled cannabinoid trials for pain, participants receiving placebo often reported substantial improvement. A comparison with their own starting scores also includes ordinary fluctuations in symptoms and changes that accompany taking part in a study. The placebo group’s experience cannot be divided neatly into those ingredients from the score alone.

Put a time beside each treatment guess, record the reason, preserve uncertainty and show the pain ratings from both groups. The result is a much more legible experiment. A volunteer’s final guess may be correct for an excellent reason that nobody designing a better-looking placebo could ever disguise: she has already lived through the outcome the researchers came to measure.